NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Altre lingue Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Azioni

603707

CNE100002WP3

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 17/05/2024			Variaz. 5gg	Var. 1 gen.
13,81 ^CNY	+2,60%		-0,65%	-7,93%

13/05	L'unità di NKFPharma ottiene l'approvazione della FDA per la commercializzazione dell'iniezione di eptifibatide negli USA	MT
01/05	NKFPharma ottiene l'autorizzazione a registrare un nuovo trattamento contro il cancro	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US	13/05
NKFPharma Gets Nod to Register New Cancer Treatment	01/05
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	16/01
NKFPharma Gets Certificate to Register Voriconazole for Injection	11/01
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	28/12
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	22/12
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21/09/23
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	17/08/23
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	26/07/23
NKFPharma Unit Gets US FDA Nod for Cancer Drug	21/07/23
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	27/06/23
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	10/05/23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23
NKFPharma Gets Certification for Lung Cancer Drug	11/04/23
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	21/02/23
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	15/12/22
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Azioni

603707

CNE100002WP3

Altre lingue

Filtri